iScience, Volume 27

Supplemental information

CREB3L4 promotes hepatocellular carcinoma

progression and decreases sorafenib chemosensitivity

by promoting RHEB-mTORC1 signaling pathway

Zhengchen Jiang, Bowen Shi, Yun Zhang, Tianming Yu, Yang Cheng, Jiankang Zhu, Guangyong Zhang, Mingwei Zhong, Sanyuan Hu, and Xiaomin Ma

Supplementary Table 1 Clinicopathological characteristics of HCC patients, related to

Characteristics	Cohort 1 (n=83)	Cohort 2 (n=20)		
Gender				
Male	71(85.5%)	16(80.0%)		
Female	12(14.5%)	4(20.0%)		
Age				
<60 yrs	59(71.1%)	12(60.0%)		
≥60 yrs	24(28.9%)	8(40.0%)		
Liver cirrhosis history				
Yes	18 (21.6%)	10(50.0%)		
No	65 (78.4%)	10(50.0%)		
TNM stages				
Ι	7(8.4%)	4(20.0)		
П	47(56.7%)	9(45.0%)		
III	29(34.9%)	7(35.0%)		
IV	0(0%)	0(0%)		
Pathological staging				
Ι	16(1.1%)	8(40.0%)		
П	59(45.6%)	10(50.0%)		
III	8(53.3%)	2(10.0%)		

STAR Method (Clinical samples)

Cohort 1 was derived from the HCC tissue chip purchased from Outdo Biotech (Shanghai, China). Cohort 2 was derived from patients with HCC admitted to our hospital for treatment.

LV-shNC

LV-shCREB3L4





Supplementary Figure 1 Construction of stable infection of HUH7 cells with Lentivirus (LV)shCREB3L4 plasmid, related to STAR Method (Construction of stable infection of HUH7 cells with Lentivirus (LV)-shCREB3L4 plasmid).

(A) Lentiviral transfection of HUH7 cell lines was performed using a MOI of 10 or 20 viral loads, and the fluorescence intensity was observed under the microscope.
(B) The qRT-PCR was performed to detect the effective knockdown of HUH7 cells infected with LV-shCREB3L4 after infected for 4 weeks.
(C) The qRT-PCR was performed to detect the effective knockdown of dissected tumors.



Supplementary Figure 2 Basal level of CREB3L4 in HCC cell lines and clinic samples, related to Figure 1. (A) Western blot assay was conducted to measure the relative expression of the CREB3L4 protein in HUH7, Hep3B cells, tumor tissues (T) and the normal tissues (NT). Western blot bands were analyzed by ImageJ software. (B) qRT-PCR analysis was conducted to measure the relative expression of the CREB3L4 mRNA in HUH7, Hep3B cells, tumor tissues (T) and the normal tissues (NT).

В



Supplementary Figure 3 Combination index values of rapamycin, related to Figure 3. (A) HUH7 cells (1×104 cells/well) were transfected with different dosages of shCREB3L4 plasmid ($0.5 \mu g/ml$, $1 \mu g/ml$, and $2 \mu g/ml$) and different dosages of rapamycin (20 nM, 40 nM, and 80 nM). Cellular viability was detected by CCK-8 assay after treating with shCREB3L4 and rapamycin for 48 hr. Combination index values were calculated by Compusyn software, and drug interaction was indicated as synergism (CI < 0.9), additivity (0.9 < CI < 1.1) or antagonism (CI > 1.1).



Supplementary Figure 4 RHEB knockdown reversed the promoting effects of CREB3L4 on the proliferation of HUH7 and Hep3B cells, related to Figure 4. (A) HUH7 and Hep3B cells were transfected with CREB3L4 overexpressing plasmid or siRHEB. Approximately 24 hr after transfection, cells were treated with sorafenib (10 μM) for 48 hr. Colony formation assay was performed to detect the proliferation of the cells. (B) Cell proliferation was detected by EdU assays. * P <0.05, **P <0.01, ***P <0.001 for statistical analysis of the indicated groups.



Supplementary Figure 5 Combination index values of sorafenib, related to Figure 5.

(A) HUH7 cells (1×104 cells) were transfected with different dosages of shCREB3L4 plasmid ($0.5 \mu g/ml$, $1 \mu g/ml$, and $2 \mu g/ml$) and different dosages of sorafenib ($5 \mu M$, $10 \mu M$, and $20 \mu M$). Cell viability was detected by CCK-8 assay after treating with shCREB3L4 and sorafenib for 48 hr. Drug interaction was indicated as synergism (CI < 0.9), additivity (0.9 < CI < 1.1) or antagonism (CI > 1.1).



Data S1 Original images of Western blot, related to Figure 1E.



Data S2 Original images of Western blot, related to Figure 2C.



Data S3 Original images of Western blot, related to Figure 2D.

HA- CREB3L4 43KD	
p-mTOR 289KD	
mTOR 289KD	
p-S6K1 70KD	
S6K1 70KD	
p-S6 32KD	
S6 32KD	3
P-4E-BP1 17KD	
4E-BP1 17KD	
GAPDH	

Data S4 Original images of Western blot, related to Figure 3A.

36KD

HA- CREB3L4 43KD	
p-mTOR 289KD	
mTOR 289KD	
p-S6K1 70KD	-8
S6K1 70KD	
p-S6 32KD	
S6 32KD	
P-4E-BP1 17KD	** **
4E-BP1 17KD	
GAPDH 36KD	

Data S5 Original images of Western blot, related to Figure 3A.

CREB3L4 43KD	
p-mTOR 289KD	
mTOR 289KD	
p-S6K1 70KD	
S6K1 70KD	
p-S6 32KD	
S6 32KD	83
P-4E-BP1 17KD	
4E-BP1 17KD	-
GAPDH 36KD	

Data S6 Original images of Western blot, related to Figure 3B.

CREB3L4 43KD	
p-mTOR 289KD	
mTOR 289KD	
p-S6K1 70KD	
S6K1 70KD	
p-S6 32KD	
S6 32KD	
P-4E-BP1 17KD	== ==
4E-BP1 17KD	
GAPDH 36KD	

Data S7 Original images of Western blot, related to Figure 3B.



Data S8 Original images of Western blot, related to Figure 3C.







Data S10 Original images of Western blot, related to Figure 4D.



Data S11 Original images of Western blot, related to Figure 5G.

CREB3L4 43KD	====
RHEB 16KD	
P-mTOR 289KD	
mTOR 289KD	
P-S6K1 70KD	
S6K1 70KD	
P-S6 32KD	
S6 32KD	== ====
GAPDH 36KD	

Data S12 Original images of Western blot, related to Figure 5G.



Data S13 Original images of Western blot, related to Figure 5H.



Data S14 Original images of Western blot, related to Figure 5H.



Data S15 Original images of Western blot, related to Figure 6C.



Data S16 Original images of Western blot, related to Figure 6D.



Data S17 Original images of Western blot, related to Supplementary Figure 1A.